Lilly Taltz Meets Key Endpoints in Pediatric Plaque Psoriasis

Eli Lilly & Co. (LLY) on Monday said its psoriasis drug Taltz met the co-primary endpoints and all major secondary endpoints in a phase 3 study in pediatric patients with moderate to severe plaque psoriasis.

The Indianapolis drug maker said that based on the study results, it plans to file for U.S. Food and Drug Administration approval for pediatric patients with the chronic autoimmune skin condition.

Eli Lilly said the study showed that Taltz, which is already approved to treat adults to with moderate to severe plaque psoriasis, may have the potential to clear skin and reduce itch in pediatric patients.

https://www.marketscreener.com/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-Taltz-Meets-Key-Endpoints-in-Pediatric-Plaque-Psoriasis-29468487/